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ABSTRACT 
 
Type I interferons (IFNs) are potent inducers of the first-line defense against pathogens. Their 
activity leads to the up- and downregulation of a large number of genes with various effects on the 
immune system, including direct effects on the pathogens. Due to the strong response evoked by 
IFN signaling, the IFN pathway is tightly regulated by IFN stimulated genes to avoid detrimental 
effects of long-term exposure. If the IFN signaling pathway is not regulated properly, or for other 
reasons constantly activated, it can lead to interferonopathies and autoimmune diseases such as 
systemic lupus erythematosus (SLE) and Sjögren’s syndrome (SS). Indeed, many therapeutics 
targeting the IFN pathway are currently in clinical trials. In contrast, type I IFNs are used to treat 
certain types of cancer, virus infections and multiple sclerosis. The complex role of type I IFN 
signaling in disease is not well understood and need further characterization for better therapeutic 
inventions. 
 
The aim of this thesis was to identify genes that are regulated by type I IFNs and investigate their 
role in the immune system. To do this, we quantified the expression of interferon-regulated genes 
in sorted immune cells from patients with primary SS, and from individuals treated with IFNb. 
Using global gene expression analysis on PBMCs as well as qPCR on sorted cells, we could identify 
several genes that were differentially regulated by type I IFNs in different immune cell populations. 
Among them were TRIM21 that was upregulated in T cells and B cells, BAFF that was upregulated 
in T cells, monocytes and neutrophils and miR-150-5p that was selectively downregulated in 
monocytes. The downregulated expression of miR-150-5p consequently led to an increased 
expression of its target c-Myb. In addition, monocytes from patients with SLE displayed an increase 
in c-Myb target genes. When investigating the regulation of BAFF and TRIM21, we found that 
both were regulated by members of the interferon regulatory factor (IRF) family. Specifically, both 
were upregulated by IRF1 and IRF2, and downregulated by IRF4 and IRF8. To further investigate 
the role of TRIM21 in the immune system, we generated Trim21-/- mice. These mice were prone to 
granulocyte infiltrations and developed symptoms of autoimmune disease after being triggered by 
metal ear tags. We found that TRIM21 negatively regulates the immune response by ubiquitinating 
IRFs, and that naïve Trim21-/- mice control the development of eosinophils in the bone marrow. 
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1. INTRODUCTION 
 
In the early 1950’s Nagano and Kojima observed an anti-viral agent in rabbit skin infected with 
vaccinia virus (1). Isaacs and Lindenmann later discovered and named the factor causing this 
antiviral state “interferon” (IFN) (2). Not until 20 years later, Rubinstein and colleagues published 
the purification of IFN (3). In 1980, Taniguchi et al. and Mantei et al. published the first successful 
cloning of IFN (4, 5). IFNs turned out to be a family of proteins consisting of IFN type I, II and 
III. IFNa, IFNb, IFNe, IFNk and IFNw are collectively called type I IFNs, and they are the largest 
class of IFNs. Thirteen human genes that code for twelve different IFNa proteins, and only one 
single gene each that codes for the human IFNb, IFNe, IFNk and IFNw proteins, have been 
described. IFNg is the only member of the type II IFN subclass, while type III is the most recently 
described subclass consisting of IFNl1, IFNl2 and IFNl3. This thesis will address type I IFNs 
and its effector genes.  
 
1.1. Type I IFN signaling 
 
1.1.1. Classical signaling pathway 
All type I IFNs share the same ubiquitously expressed receptor consisting of two chains, 
interferon-a/b receptor (IFNAR) 1 and IFNAR2. IFNAR1 constitutively associates with tyrosine 
kinase 2 (TYK2) and IFNAR2 with Janus kinase 1 (JAK1) (6, 7). Binding of type I IFNs to its 
receptor leads to the activation of the JAK-STAT (signal transducer and activator of transcription) 
signaling pathway (8, 9). After dimerization of the receptor subunits, TYK2 and JAK1 are activated 
followed by phosphorylation of intracellular tyrosine residues on IFNAR, creating docking sites 
for STATs. STATs are then recruited to the intracellular domain of the receptor and bind the 
docking site through their Src-homology 2 (SH2) domains followed by phosphorylation of STATs 
on tyrosine residues (10, 11). Phosphorylated STAT1 and STAT2 form a complex together with 
interferon-regulated factor (IRF) 9, called interferon-stimulated gene factor 3 (ISGF3), which in 
turn is transported into the nucleus where it can bind to a transcription factor binding site named 
interferon-stimulated response element (ISRE) and activate gene transcription (8, 10, 11). Type I 
IFN signaling can also active other STAT homo- and heterodimers which binds to the IFNg-
activated site (GAS) (12, 13).  
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Fig. 1. Type I IFN signaling. Binding of type I IFN to its receptor leads to the activation of the 
JAK-STAT pathway in which JAK1 and TYK2 phosphorylates STATs. Phosphorylated STAT1 
and STAT2 forms a complex together with IRF9 called ISGF3 that can bind to ISRE in the nucleus 
and activate gene expression. Phosphorylated STAT homo- or heterodimers on the other hand can 
bind to GAS-elements and activate gene expression. 
   
1.1.2. Non-classical signaling pathways 
IFNAR can also signal via other pathways than the JAK-STAT signaling pathway, particularly the 
p38 mitogen-activated protein kinase (MAPK) and phosphatidylinositol 3-kinase (PI3K) pathways.  
 
1.1.2.1. The p38 MAPK pathway 
p38 is activated by an upstream phosphorylation cascade where each kinase act as a substrate for 
the other. p38 is phosphorylated by MAPK kinase (MAPKK), which is phosphorylated upstream 
by other kinases in the phosphorylation cascade. The activation of the IFN signaling pathway via 
p38 is not fully understood, but the G-protein Rac1 seems important and is activated by upstream 
kinase activity, possibly a JAK (14). The downstream effect of the p38 MAPK pathway ultimately 
leads to the activation of two serine kinases, MAPKAPK2 and MAPKAPK3. It is not known how 
p38 activates the transcription of interferon-stimulated genes (ISGs), however evidence so far 
indicates that the p38 MAPK pathway is essential for the transcription of ISGs (15). 
 
	 3	
1.1.2.2. The PI3K pathway 
Members of the type I IFN family can induce the phosphorylation of insulin receptor substrate 
(IRS) 1 and 2, and PI3K associates with IRS, followed by activation of PI3K, in an IFN-dependent 
manner downstream of JAKs (13). Protein kinase C (PKC) d is activated by IFNs and has been 
proposed to phosphorylate STAT1 on Ser727 (16).  IFNg-stimulated cells in which the PI3K 
activity has been inhibited cannot phosphorylate STAT1 on Ser727, leading to reduced levels of 
STAT1 transcripts (17). Taken together, these data suggest that the IFN-mediated activation of the 
PI3K pathway leads to the phosphorylation of STAT1 on Ser727 (13). The phosphorylation on 
Ser727 in STAT1 is not essential for STAT1 binding to ISG promoters, but for full transcriptional 
activation (18, 19). 
 
1.2. The production of type I IFNs 
 
Type I IFNs can be produced by all nucleated cells in response to the activation of pattern 
recognition receptors (PRRs). Cytosolic PRRs that recognize nucleic acids from viruses are the 
predominant receptors responsible for type I IFN production in most cells. The activation of some 
Toll-like receptors (TLRs) can however also induce type I IFNs in certain cell types such as 
macrophages and dendritic cells (DCs). One cell type is specialized in type I IFN production and 
produce large amounts after TLR activation, namely the plasmacytoid DC (pDC) (20).  
 
1.2.1. MDA5 and RIG-I 
Melanoma differentiation-associated gene 5 (MDA5) and Retinoic acid-inducible gene I (RIG-I) 
are caspase activation and recruitment domain (CARD) -containing PRRs activated by viruses. 
MDA5 and RIG-I sense different types of viruses due to their ability to recognize different RNA 
structures (21). They signal via mitochondrial antiviral-signaling protein (MAVS, also known as 
IPS-1, VISA and Cardif) and the kinases TANK-binding kinase 1 (TBK1) and IkB kinase i (IKKi) 
and activates IRF3 and IRF7 which in turn form homo- or heterodimers that enter the nucleus and 
bind to ISRE (22).  
 
1.2.2. STING and cGAS 
Stimulator of interferon genes (STING) is an immune signaling molecule associated with the 
endoplasmic reticulum (ER) that is activated by pathogen-derived or endogenous cyclic 
dinucleotides (CDNs) in the cytosol of the cell (23, 24). STING activation leads to transcriptional 
upregulation of several genes, including type I IFNs. Cytosolic DNA can activate cyclic GMP-
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AMP synthase (cGAS) to produce CDNs, known as cytosolic guanosine monophosphate-
adenosine monophosphate (cGAMP), in the presence of ATP and GTP (25). The CDNs in turn 
can activate STING, which forms a complex with TBK1 that is necessary for the delivery of TBK1 
to the endolysosomal compartment where it phosphorylates IRF3 and nuclear factor-kB (NF-kB) 
(24, 26, 27). STING has also been proposed to work as a downstream signaling molecule of DNA 
PRRs, such as DEAD-box helicase 41 (DDX41) and IFNg-inducible protein 16 (IFI16) (28). 
 
1.2.3. TLRs and pDCs 
Some members of the TLR-family can induce type I IFNs; TLR3, TLR4, TLR7, TLR8 and TLR9. 
Of these, only TLR4 is located on the cell surface while the others are endosomal. TLR4 is the 
only TLR known to induce type I IFNs in response to non-nucleic acid ligands, namely bacterial 
lipopolysaccharides (LPS). TLR3 and TLR4 can signal via the adaptor molecule TIR-domain-
containing adaptor protein inducing IFNb (TRIF) and TBK1 to activate IRF3 (29). Conventional 
DCs (cDCs) express TLR3, TLR8 and low levels of TLR2 and TLR4, pDCs however express high 
levels of TLR7 and TLR9. TLR7 and TLR9 respond to ssRNA and DNA respectively and are 
dependent on the adaptor protein myeloid differentiation primary response gene 88 (MyD88) for 
signal transduction. Only in pDCs, TLR7 and TLR9 are efficient type I IFN-producers due to their 
constitutive expression of IRF7 (30). The MyD88 and IRF7 complex is retained in the endosomal 
compartment and induces type I IFNs in a spatiotemporal regulatory manner (31).  
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Fig. 2. Type I IFN induction. Cytosolic PRRs recognize RNA and DNA, and signal via MAVS 
and STING respectively as well as the kinase TBK1.  TLR3 in the endosome, and TLR4 on the 
cell surface, can signal via TRIF and TBK1. TBK1 signaling ultimately leads to IRF3 activation 
and type I IFN production. Endosomal TLR7 and TLR9 can activate the MyD88 pathway upon 
type I IFN stimulation, and activate IRF7 exclusively in pDCs. 
 
1.3. Interferon regulatory factors 
 
IRFs are transcription factors acting under PRRs. The mammalian family of IRFs consists of 9 
members, IRF1-IRF9, all containing a well-conserved DNA-binding domain that recognizes ISRE 
(A/GNGAAANNGAAACT) (10). IRF1, IRF3, IRF5 and IRF7 have been described as important 
for type I IFN gene transcription (32). The IRF1 gene was the first IRF reported to bind type I 
IFN gene promoters, however it seems redundant for type I IFN expression (33). IRF3 and IRF7 
are key regulators of type I IFN expression. IRF3 is constitutively expressed while IRF7 is 
expressed in small amounts in all cells, and induced by type I IFN signaling via the ISGF3 complex 
(32). TBK1 and IKKi are the virus induced tyrosine kinases that activates IRF3 and IRF7 (34, 35).  
 
In addition to IRF7, IRF5 can also be activated by the TLR7/TLR9-pathway, bind to MyD88 and 
subsequently initiate gene transcription (36). IRF4 has also been reported to bind MyD88, and has 
been suggested to compete with IRF5 to inhibit MyD88-dependent IRF5 activation in T cells, B 
cells and macrophages where IRF4 is mainly expressed (37, 38). IRF8 is also an immune-specific 
IRF but contrary to IRF4, it increases TLR9-signalling (39). IRFs form various heterodimers 
between each other (except IRF1 and IRF2), but can also form complexes with other proteins. 
IRF4 and IRF8 for an example, can act as transcription repressors by binding to ETS/ISRE 
domains when bound to ETS-family transcription factor PU.1 (32, 38). 
 
Several IRFs are also regulating immune cell development, e.g. IRF4 is required for plasma cell 
differentiation, for differentiation of CD4+ DCs, for Th2 differentiation and supports B cell 
development; IRF8 is required for the development of CD8a+ DCs and pDCs, stimulates 
macrophage differentiation, supports B cell development and promotes Th1 differentiation 
through macrophages and DCs (38, 40).  
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1.4. Interferon-regulated genes 
 
Type I IFN signaling consequently leads to the up- and downregulation of a large number of genes 
(10). These genes are involved in numerous biological processes, such as anti-viral and anti-
intracellular bacterial defense, immune regulation, apoptosis, cell differentiation etc. The regulatory 
mechanisms that induce ISGs are well-characterized and have been extensively described in this 
thesis. However, the mechanisms that leads to the downregulation of genes by type I IFNs is not 
well-characterized. miRNAs that are regulated by IFNs could play an important role in this 
downregulation of gene expression (41). Genes that are up- and downregulated following IFN-
stimulation are collectively called interferon-regulated genes (IRGs). The Interferome 
(www.interferome.org) is a database collecting information from high-throughput experiments 
containing type I, II and III IRGs. IRGs in the Interferome database are identified from organisms 
or cells treated with IFNs, and defined as statistically up- or downregulated genes with a 2-fold 
change in expression. With these generous definition parameters, around 3000 genes are classified 
as IRGs in human and mouse (42). 
 
1.4.1. ISGs in viral defense 
ISGs can inhibit different stages of the virus life cycle. For an example, myxovirus resistance 1 
(MX1) inhibits an early stage of the virus life cycle by forming ring-structures around nucleocapsids 
to trap them (43). Another example of an ISG that can inhibit viruses at an early stage is tripartite 
motif-containing (TRIM) protein 5a. This protein can bind to the retroviral capsid of HIV-1 and 
accelerate its cytoplasmic uncoating (44). TRIM5a is only one of many members in the TRIM 
family with anti-viral effects (45). Members of the 2’-5’ oligoadenylate synthase (OAS) family on 
the other hand, can inhibit dsRNA viral replication by activating the endoribonuclease RNase L to 
degrade viral transcripts (43). During the late stages of the virus life cycle, its nucleic acids are 
packed into capsids before it exits the cell. Tetherin is a protein that inhibits virus budding by 
trapping virions on the plasma membrane (46, 47). Due to the multifaceted anti-viral response by 
type I IFNs, many viruses have developed mechanisms to inhibit IFN-signaling and ISGs (48). 
 
1.4.2. ISGs and immune regulation 
Since IFN-signaling leads to a strong immune response, the IFN pathway is tightly regulated by 
ISGs to avoid detrimental effects of long-term exposure. One example is suppressor of cytokine 
signaling (SOCS) proteins that inhibits JAK-STAT signaling by inhibiting JAK enzymatic activity 
(49). Another example are members of the TRIM protein family, in which many or potentially all 
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are E3 ligases that are involved in both the positive and negative regulation of the IFN response 
(50). E.g. TRIM21 can ubiquitinate and negatively regulate members of the IRF family and DDX41 
(51-55).  
 
 
Fig. 3. Type I IFNs regulate numerous biological processes via IRGs. Infection by e.g. a 
virus, leads to the up- and downregulation of a large number of IRGs. These can in turn e.g. act in 
the direct defense against the pathogen, regulate the immune system, induce apoptosis or affect 
cell differentiation.  
 
1.5. Type I IFNs in immune disorders and disease 
 
Since its discovery, the role of type I IFNs in clearing viral infections has become evident. However, 
aberrant IFN-signaling has emerged as an important feature in several autoimmune and 
autoinflammatory disorders. In contrast, type I IFNs is successfully used to treat multiple sclerosis 
(MS) and certain types of cancer. The complex role of type I IFN signaling in disease is not well 
understood and need further characterization for better therapeutic inventions. 
 
1.5.1. Type I interferonopathies 
Genetically determined disorders driven by type I IFNs are collectively called interferonopathies. 
The type I IFN response can result due to several reasons; enhanced levels or abnormal chemical 
modifications of endogenous nucleic acids, constant activation or enhanced sensitivity of the type 
I IFN pathway in a ligand-independent manner, or defects in the negative regulation of the type I 
IFN pathway, either dependent or independent of nucleic acid sensing (56). Definitive proof that 
type I IFN is causing the pathology behind these diseases is lacking, however many of these diseases 
have clinical phenotypic overlaps (57). A few examples of type I interferonopathies are Aicardi-
Goutiéres syndrome (AGS), systemic lupus erythematosus (SLE) and interferon-stimulated gene 
15 (ISG15) deficiency. AGS was the first monogenic disorder described to have increased type I 
IFN activity, and some of the proteins in which the gene is mutated in AGS include DNA 3’ repair 
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exonuclease 1 (TREX1), adenosine deaminase acting on RNA (ADAR) and MDA5 (58). TREX1 
is a nuclease that target ssDNA and dsDNA and ADAR is a dsRNA-editing enzyme.   
 
1.5.2. Pathological mechanisms behind SLE and SS 
SLE is a complex systemic autoimmune disease where genetic background as well as environmental 
factors contribute to pathology. In only a small fraction of patients (<5%), a mutation in a single 
gene is thought to be causative for disease (59), and of those even less have mutations where 
evidence can predict an upregulation of type I IFNs (57). Therefore a very small proportion of 
SLE cases qualify as monogeneic type I interferonopathies as defined by Rodero and Crow (57). 
Nonetheless, many adult SLE patients and nearly all pedriatic SLE patients display an ‘IFN 
signature’ (60, 61). The IFN signature is defined by elevated levels of ISGs in the blood, and is 
observed in several systemic autoimmune conditions including Sjögren’s syndrome (SS) and 
rheumatoid arthritis (RA) (62, 63). Type I IFN mRNA levels are hard to detect in healthy 
individuals, even after vaccination, and also in interferonopathies (57). Therefore, a screening for 
ISG expression levels is more informative.  
 
SLE is characiterized by the autoantibody production against components of the cell nucleus and 
a wide array of clinical manifestations such as inflammation, vasculitis, immune complex 
deposition, fatigue and glomerulonephritis. Type I IFNs, mainly IFNa, seem to be an important 
mediator responsible for many of the immunological features leading to clinical disease in SLE 
patients (64). Some patients with virus infections and certain cancer types that are treated with type 
I IFNs develop SLE or symptoms of SLE, that in many cases are transient and ceases to appear 
when the IFN-treatment is discontinued (65-67). This strongly suggests that ISGs are in fact 
responsible for the pathology behind the development of SLE. 
 
The main hypothesis as to how ISGs are induced in SLE suggests an important role of the 
endogenously activated TLR7/TLR9-induced expression of type I IFN in pDCs (68). In this 
model, RNA and DNA are released from apoptotic cells and accumulate due to reduced clearing 
of apoptotic cells in SLE patients. Anti-nuclear antibody- (ANA) RNA/DNA complexes are then 
endocytosed by pDCs and activate IFN-production via IRF7 (69). Type I IFNs in turn activate 
DCs and upregulate major histocompatibility complex (MHC) and costimulatory molecules leading 
to the activation of autoreactive T cells (70-72). They also induce the production of B cell activating 
factor (BAFF) and a proliferation-inducing ligand (APRIL) that promote B cell survival, 
differentiation and isotype switching (73).  
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SS is an autoimmune disease with some clinical overlap with SLE, such as autoantibodies towards 
TRIM21/Ro52 and the IFN signature. Also in this disease, the IFN-signature and consequently 
the upregulation of BAFF is proposed to have an important role in the pathogenesis (74). Patients 
with SS have a predisposition towards inflammation in exocrine glands leading to sicca symptoms, 
such as dry eyes and dry mouth. SS can occur in combination with other autoimmune diseases, 
such as SLE, and is then called secondary SS. If the patient is only diagnosed with SS, it is referred 
to as primary SS (pSS). 
 
1.6. Type I IFNs in therapy 
 
1.6.1. Targeting the IFN pathway 
With the emerging evidence that type I IFNs play an important role in the development of immune 
disorders with an IFN-signature, a number of new therapeutic strategies targeting the IFN-pathway 
are in clinical trials. The only established treatment so far targeting the IFN pathway in SLE is 
hydroxychloroquine (HCQ) (75). HCQ is an antagonist of endosomal TLRs by reducing 
endosomal acidification. Two anti-IFNa monoclonal antibodies (mAbs) have completed phase II 
clinical trials for SLE, sifalimumab and rontalizumab (76, 77). Both studies showed promising 
results with decreased disease activity and a decrease in the IFN-signature compared to placebo. 
Both drugs appeared to be safe, however sifalimumab-treated patients more frequently had herpes 
zoster infections. Despite the promising results, none of these molecules were chosen for phase 
III studies. On the other hand, a phase II study on anifrolumab, a mAb blocking IFNAR2 and 
thereby inhibits type I IFN signaling, indicated a more efficacious outcome for SLE patients (78). 
This molecule has been chosen for a phase III clinical trial. In addition, several molecules targeting 
JAKs have been developed. Tofacitinib, targeting JAK1 and JAK3, is approved for clinical use in 
RA and is in phase I clinical trials for SLE (75). There are also several other therapeutics targeting 
different nodes of the IFN pathway, such as TLRs and pDCs, in early clinical trials (75).  
 
Targeting the IFN response has so far showed promising results in some systemic autoimmune 
diseases and further strengthen the evidence that type I IFNs are the driving force behind these. 
 
1.6.2. IFN as therapy 
Due to the pro- and anti-inflammatory, anti-viral and anti-cancer properties of type I IFNs, it is 
used to treat certain cancers, viral infections and also MS. In cancer, IFN has both direct effects 
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on the cancer cells, such as anti-proliferative and pro-apoptotic effects, and indirect by enhancing 
the immune response towards the cancer cells. Cancer cells can develop an IFN-resistance by e.g. 
downregulating type I IFN genes and receptors, indicating that type I IFNs are important for killing 
cancer cells. However, IFN treatment has had varying success. Recent trials indicate that combining 
IFN treatment with other therapies might be more beneficial (79).  
 
In MS, IFNb was the first therapy to show clinical efficacy and is still the most common first-line 
treatment. However, 40% of the patients do not respond, or respond poorly, to IFNb (80). MS is 
an inflammatory disease of the central nervous system caused by demyelination of the nerves. It is 
still not known how IFNb improves the clinical outcome of MS, but its anti-inflammatory activities 
are thought to be responsible. In a mouse model for MS, experimental autoimmune 
encephalomyelitis (EAE), type I IFNs were shown to inhibit Th17 development and thus provide 
a possible clue to the beneficial effects of type I IFNs in MS (81). Interestingly, an IFN signature 
was identified in a subset of the most common type of MS, relapsing-remitting MS (RRMS), and 
an increased baseline level of ISGs was associated with a lack of response to IFNb (82, 83). Thus, 
the IFN signature can be used to predict clinical efficacy of IFNb treatment in MS patients.  
 
The main drawback of using type I IFNs in therapy is the large number of severe side effects, 
including influenza-like symptoms, fatigue, neurological toxicities, anorexia, depression and 
leukopenia (84). Therefore, there is a great need of finding therapeutic options for treating these 
diseases.  
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2. AIMS 
 
The overall goal of this thesis was to identify new IRGs and investigate how they are regulated and 
what their roles are in the immune system. The rationale behind this is that IRGs can help us 
understand the complex nature of type I IFN signaling and its role in immune disorders. To reach 
this goal, we set up these aims: 
 - Identify human IRGs that could play a role in disease (paper I, II, III, IV and V) - Identify regulatory elements in selected IRGs and test their functionality (paper II and III) - Investigate human material or knock-out mice to identify a role for the IRGs in the immune 
system and/or immune disorders (paper I, IV and V) 
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3. RESULTS 
 
3.1. Differences in IFN signature between major immune cell populations  
 
(Paper I, II, III, IV and V) 
 
We aimed to identify genes that are regulated by type I IFNs and investigate their role in the 
immune system. To do this we quantified the expression of IRGs in sorted immune cells from 
patients with pSS, and from individuals treated with IFNb.  
 
Since many patients with systemic autoimmune disease display an IFN signature with elevated 
levels of ISGs, we collected blood samples from patients with primary Sjögren’s syndrome (pSS) 
and healthy controls and performed a gene expression array (62, 85, 86). When comparing patients 
with an IFN signature to controls without an IFN signature, we observed that many well-known 
ISGs such as MX1 and OAS2 were upregulated in patients. We also observed that many members 
of the TRIM gene family were differentially regulated in patients.  
 
Feng et al. describe that different cell populations can respond differently to IFN stimulation due 
to varying abundance of the epigenetic marker H3K9me2 on the ISG promoters (87). To 
investigate the cell-specific regulation of some of the genes we identified in the pSS patients, we 
collected new blood samples from pSS patients and controls with sicca symptoms and sorted the 
cells into CD14+ monocytes, CD3+ T cells, CD19+ B cells and CD15+ neutrophils. In the pSS 
patients, we could observe that the classical ISGs MX1 and OAS2 were upregulated in all cell 
populations. However, individual TRIM genes were differentially regulated only in certain 
populations. For an example, TRIM1 (MID2) was most prominently downregulated in CD19+ B 
cells and to some extent in CD3+ T cells (Sjöstrand et al., unpublished data). TRIM25 was 
upregulated in the same populations (Sjöstrand et al., unpublished data). To validate that these 
genes were differentially regulated as a result of IFN signaling and also to observe an acute IFN 
response rather than a chronic, we collected gene expression data in blood samples from patients 
with MS before and approximately 18 hours after de novo IFNb (AvonexÒ) administration and 
sorted these cells into the same populations as in the pSS patients. We could confirm the 
upregulation of TRIM25 in only T cells and B cells (Sjöstrand et al., unpublished data). We could 
also see a clear induction of TRIM21 in only T cells and B cells. Additionally, we observed that 
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BAFF was upregulated significantly in T cells, monocytes and neutrophils and with the same trend 
in B cells, however not significant.  
 
To identify miRNAs that are regulated by type I IFNs, we performed a TaqMan-based miRNA 
gene expression array (754 genes) on one MS patient with a strong response to IFNb (based on 
MX1 and OAS2 expression levels), on T cells and monocytes before and 18 h after IFNb 
administration. We identified a number of miRNAs that could potentially be regulated by type I 
IFNs, including miR-150-5p that was strongly repressed in monocytes. We confirmed the results 
from the initial miRNA profiling in all sorted populations from all patients included in the study 
and confirmed reduced levels of miR-150-5p selectively in monocytes.  
 
Collectively, we could identify several genes that were differentially regulated by type I IFNs in 
different immune cell populations. Among them were TRIM21 that was upregulated in T cells and 
B cells, BAFF that was upregulated in T cells, monocytes and neutrophils and miR-150-5p that was 
selectively downregulated in monocytes. We chose to study these three genes in more detail: how 
they are regulated by type I IFNs and what their role is in the immune system. 
 
3.2. Type I IFNs reduces microRNA-150-5p levels in monocytes and activates a 
c-Myb transcriptional program  
 
(Paper I) 
 
After identifying miR-150-5p as a miRNA that is downregulated after IFNb administration in MS 
patients, we wanted to investigate how this occurs in more detail. We found that the transcript 
levels of pri-miRNA-150 were not affected by IFNb, suggesting that the reduced levels of mature 
miRNA-150-5p were due to either decreased maturation of pri-miR-150 or increased release of 
miR-150-5p from monocytes. Since monocytes have previously been reported to secrete miR-150-
5p, we wanted to test if this was the case in our patient samples (88). We therefore isolated plasma 
miRNAs from MS patients before and after IFNb administration and observed a strong reduction 
of plasma miRNA-150-5p, indicating that IFNb blocks miR-150 maturation rather than effect its 
secretion from monocytes. 
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There is evidence that the IFN signature displayed in patients with the systemic autoimmune 
disease SLE is driving the disease (89). We were therefore wondering if miR-150-5p was also 
reduced in SLE patients. Indeed, miR-150-5p was reduced in PBMCs and cells from CSF compared 
with healthy controls and MS patients with an inflammatory disease but without an IFN signature. 
miR-150 post-transcriptionally regulates c-Myb, a transcription factor important for hematopoiesis 
(90, 91). We then wondered if c-Myb target genes were over-expressed in SLE patients. Indeed, 
we could see that c-Myb target genes were over-represented in gene expression data from 
monocytes in pediatric SLE patients (GSE46907) (92).  
 
In summary, we identified miR-150-5p as an IFN-regulated miRNA selectively down-regulated in 
monocytes. Additionally, we observed that in SLE patients with an IFN signature, miR-150-5p was 
downregulated leading to an activation of a c-Myb transcriptional program.   
 
3.3. The ISGs BAFF and TRIM21 are controlled by transcription factors of the 
interferon regulatory factor (IRF) family 
 
(Paper II and III) 
 
Both TRIM21 and BAFF were upregulated in humans as a result of type I IFN signaling, 
prompting us to investigate the molecular mechanism underlying this. First we set out to determine 
if TRIM21 was also regulated by IFNs in mice. We stimulated a mouse T cell line (EL-4) and 
mouse splenocytes with type I and II IFNs and could observe that TRIM21 was indeed upregulated 
after the addition of IFNs. From now on, the studies of TRIM21 gene expression is on the mouse 
gene while the studies of BAFF expression is on the human gene.  
 
To identify putative regulatory elements in the promoter region of these genes, we compared the 
promoter region of BAFF and TRIM21 between different species to find conserved transcription 
factor binding sites. In both genes, we could find a highly conserved IFN-stimulated response 
element (ISRE), TRIM21 containing three GAAA repeats and BAFF containing two GAAA 
repeats, upstream of the transcription start site. Importantly, we could not find a conserved IFNg 
activated site (GAS) in neither of the two genes. To investigate if the identified ISRE sites were 
functional, we generated luciferase reporter constructs containing each of the ISREs. Since 
members of the IRF family are known to bind ISRE (93), we performed a luciferase reporter assay 
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after the co-transfection of the reporter construct together with a panel of IRFs into HEK293T 
cells. IRF1 and IRF2 could induce expression of both constructs while IRF4 and IRF8 blocked 
expression. IRF1 and IRF2 failed to induce expression of a mutated version of the reporter 
constructs where the core GAAA elements were altered into AAAA.  
 
Since TRIM21 was also upregulated after IFNg stimulation despite the lack of a GAS element, we 
speculated that IFNg stimulated the expression of IRF1 which in turn would bind to the ISRE 
rather than the direct binding of STAT homodimers. To test this, we pre-treated EL-4 cells with 
cycloheximide (CHX) to block de novo protein synthesis and stimulated the cells with type I and II 
IFNs followed by analysis of IRF1, STAT1 and Trim21 expression. CHX completely blocked the 
induction of nuclear IRF1 expression while STAT1 expression was only mildly affected. 
Importantly, Trim21 induction was greatly reduced after CHX treatment indicating that IRF1 is 
required for optimal TRIM21 induction while STAT1 is not. 
 
In summary, we concluded that TRIM21 and BAFF are true ISGs whose expression is regulated 
by members of the IRF transcription factor family. 
 
3.4. TRIM21 is a negative regulator of innate immune responses 
 
(Paper IV) 
 
To understand the role of the ISG TRIM21 in the immune system, we generated Trim21-deficient 
GFP-reporter mice. Using the GFP-reporter to detect TRIM21 expression, we found that TRIM21 
was primarily expressed in immune tissues and to some extent in endothelial cells. Trim21-/- mice 
appeared normal and had no differences in frequencies of the major immune cell populations. 
However, CD3+ T cells had an increased frequency of activated T cells (CD62Llow).  
 
While there was no apparent immune phenotype in naïve mice, over 90% of Trim21-/- mice that 
were tagged with metal ear clips developed severe dermatitis with ulcerations and granulocyte 
infiltrations. Trim21+/+ littermates on the other hand, had no reaction to the tag. Cells from draining 
lymph nodes and spleen of Trim21-/- mice produced IL-6, IL-12/IL-23p40, IL-21, IL-22, and IL-
17. IL-17 was produced by CD4+ T cells, indicating that there were elevated levels of Th17 cells at 
the site of inflammation. IL-4 and IFNg was however not increased in Trim21-/- mice compared 
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with Trim21+/+ mice. The phenotype was also replicated with low doses of the contact-sensitizing 
agent oxazolone.  
 
To investigate what caused the elevated levels of cytokines we aimed to find substrates 
ubiquitinated by TRIM21. The transcription factors IRF3 and IRF8 have previously been identified 
as targets for TRIM21 (52, 54). We hypothesized that IRF5 also might be a target of TRIM21 since 
it regulates the expression of e.g. IL-12/Il-23p40 and IL-6. Using ubiquitination assays, we 
observed that IRF5 is indeed polyubiquitinated by TRIM21. To further investigate the effect of 
TRIM21 on the activity of IRFs, we performed a GAL4 one-hybrid luciferase reporter assay. IRF3 
and IRF5 were fused to GAL4 and tested for their ability to drive luciferase expression after 
binding to a 4xGAL4-luciferase reporter. When cotransfecting with TRIM21 into 293T cells, we 
observed a decrease in IRF transcription factor activity after simulating with TLR ligands poly(I:C) 
or CpG. 
 
Since the IL-23-IL-17 pathway with a skewing towards the Th17 axis of the immune system seem 
to be activated rather than the IL-4-IFNg pathway, we hypothesized that we could rescue the 
phenotype by crossing the Trim21-/- mice with IL-23p19-/- mice. Indeed, when the IL-23-IL-17 
pathway was abolished, the Trim21-/- mice were no longer sensitive to oxazolone. 
 
In summary, we identified TRIM21 as a negative regulator of innate immune responses by 
controlling the activity of IRF transcription factors downstream of TLR signaling. 
 
3.5. TRIM21 controls eosinophil development in the bone marrow 
 
(Paper V) 
 
IFNa is successfully used to decrease eosinophil numbers in patients with hypereosinophilic 
syndrome (HES), indicating that one or several ISGs can control eosinophil homeostasis (94, 95). 
Since Trim21-/- mice are prone to granulocyte infiltration, we hypothesized that TRIM21 could be 
an ISG involved in regulating eosinophil numbers. To test this, we performed FACS on naïve 
Trim21-/- mice compared to Trim21+/+ mice and observed increased levels of eosinophils in blood 
and tissues.  
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To investigate if this was due to increased eosinopoiesis, we performed FACS on bone marrow 
cells from Trim21-/- mice compared with Trim21+/+ to identify and compare different stages during 
eosinophil development. There was no difference in levels of eosinophil progenitors nor immature 
eosinophils. However, Trim21-/- mice had increased levels of mature eosinophils.  
 
In summary, we identified TRIM21 as a novel regulator of eosinophil development.  
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4. CONCLUSIONS  
 
In this thesis, we set out to identify new IRGs and investigate their role in the immune system. We 
observed that BAFF, TRIM21 and miR-150 were regulated by type I IFNs and confirmed that 
BAFF and TRIM21 were true ISGs whose expression were controlled by members of the 
transcription factor family of IRFs. By generating Trim21-deficient mice we could conclude that 
TRIM21 regulates innate immune responses by controlling the activity of IRFs and that TRIM21 
controls the homeostasis of eosinophils in naïve mice.  
 
 
 
 
Fig. 4. Conclusions. Type I IFNs can reduce the levels of miR-150-5p in monocytes, 
consequently leading to an activated c-Myb transcriptional program. Type I IFNs stimulates the 
expression of BAFF and TRIM21 via the transcription factors IRF1 and IRF2. BAFF stimulates 
increased B cell survival, differentiation and isotype switching. TRIM21 is a negative regulator of 
the immune response by regulating IRFs. TRIM21 can also decrease the levels of eosinophils in 
the bone marrow.   
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5. DISCUSSION AND FUTURE PERSPECTIVES 
 
IFN signaling play an important role in clearing viral infections and leads to the up- and 
downregulation of a great number of genes that both activates and negatively regulates the immune 
response to control for tissue damage. IFN signaling is very powerful and the fine-tuning of the 
response is therefore very important. The expression pattern of IRGs can differ between different 
viral infections and different autoimmune diseases (96). Probably due to factors such as genetics, 
different IFN-escape mechanisms in different viruses and the acute vs chronic state in viral 
infections compared with autoimmune disease. The most studied IRGs are genes involved in viral 
defense, such as MX1 and members of the IFIT family (97). In this thesis, we used different 
approaches to identify new IRGs that could possible play a role in human disease.  
 
5.1. How should one choose important IRGs to study further? 
 
The material chosen to identify IRGs (e.g. cancer cell lines or freshly isolated tissue) will greatly 
impact the results. Therefore, it is important to carefully select a system to identify relevant IRGs. 
Our aim was to identify IRGs in human and study their regulation and function (in mouse or 
human). We therefore chose to identify IRGs that were generally affected by type I IFNs in an in 
vivo human model. For this purpose, we chose pSS patients that naturally have elevated levels of 
type I IFNs, and MS patients before and after de novo IFNb therapy. pSS patients are often 
untreated, thus reducing the risk of treatments impacting the gene expression analysis. In sorted 
cells from pSS patients, we sometimes had difficulties reaching statistical significance. The sorted 
cells were compared with persons with sicca symptoms and not healthy controls, this could explain 
the clearer results from the microarray on PBMC where pSS patients were compared with healthy 
controls. In sorted cells from MS patients, we compared the same patients before and after IFN-
treatment. This is an optimal control since individual differences in basal expression levels will be 
accounted for. Another advantage with this material is that the sample after IFNb administration 
was taken after approximately 18 hours, which makes it likely that the differences we observe in 
gene expression is due to a direct effect of IFNb.  
 
We first used a broad approach where we performed global gene expression analysis on PBMCs 
from pSS patients with an IFN-signature. We then used a more selective approach where we 
quantified selected IRGs in sorted immune cells from pSS patients. In addition, we sorted cells 
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from MS patients before and after IFNb administration and determined the expression of selected 
genes by qPCR. The benefit of this approach is that we could look at cell specific regulation and 
that we are less likely to miss differentially regulated genes due to a “dilution effect” in PBMCs or 
due to possible lymphopenia in the patients (98). The downside is that we will select genes based 
on the data from the PBMCs and cannot screen for new genes. We identified a family of genes that 
were differentially regulated, the TRIM family. The fact that many members of the same family of 
genes are differentially regulated suggests that they are true IRGs. Indeed, they have previously 
been reported to be regulated by IFNs in vitro and many of the TRIM genes contain putative ISRE 
sites (99). Comparing a chronic IFN-signature in pSS patients with an acute in IFNb-treated MS 
patients, we could confirm some of the TRIM genes expression patterns. In the MS material, we 
do not expect to identify genes that are differentially regulated due to pSS-related effects not caused 
by IFN-signaling. Comparing these two patient materials and selecting genes that are specifically 
differentially regulated in only one or the other could possibly lead to finding genes important for 
that specific disease, however in this thesis we chose to focus on genes that are generally regulated 
by type I IFNs. Also since the sorted cells were only analyzed by qPCR it was not possible to 
compare gene expression in an unbiased way. Since the TRIM family of genes were differentially 
regulated in both materials and since many TRIM genes are reported to regulate the immune system 
(50), we speculated that TRIM genes could be important IRGs in human disease. Interestingly, one 
of the TRIM genes that we identified, TRIM21, is an autoantigen in several systemic autoimmune 
diseases such as pSS and SLE. Little was previously known about its function in the immune 
system, we therefore chose to study TRIM21 in more detail. We also identified BAFF as 
differentially regulated in our material. Since BAFF has been reported to contain an ISRE (100), 
and since BAFF is targeted as therapy for SLE (101), we chose to study how it is regulated in more 
detail.  
 
When identifying IFN-regulated miRNAs, we chose monocytes and T cells from one of the MS 
patients, before and after IFNb administration. This patient was chosen based on a strong 
induction of MX1 and OAS1 expression. Choosing only one patient has its disadvantages since 
there is a huge variation between individuals due to differences in genetic background and 
environment. Since we were limited in how many arrays we could perform, we however reasoned 
that choosing one patient was better than pooling patients and risking diluting differences in gene 
expression. In this patient, we identified one miRNA that was strongly downregulated in 
monocytes, miR-150-5p. We could also confirm this by qPCR in monocytes isolated from all MS 
patients. It could also make sense to choose miRNAs that are differentially regulated in both T 
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cells and monocytes, since that would decrease the risk of choosing a false positive. We however 
found that since miR-150-5p was so strongly downregulated, made it an interesting target to verify 
and study further. miR-150-5p has previously been shown to regulate B cell differentiation by 
targeting the transcription factor c-Myb, making it an interesting gene to study in B cell driven 
autoimmune diseases such as SLE and pSS. 
 
In this thesis, I have chosen a few IRGs from our patient samples to study in more detail based on 
what is previously known in the literature about these genes. In future studies, a more systematic 
approach could be considered where each of the identified IRGs could be knocked-down/out or 
overexpressed in cell lines and then, based on the in vitro data, a few of them could be selected for 
further studies in vivo in animal models. For this you would need a very specific question, e.g. which 
IRGs affects B cell differentiation? These IRGs could then be potential targets in B cell driven 
autoimmune diseases. 
 
5.2. Can IRGs help us understand IFN-driven autoimmune diseases? 
 
Patients treated with type I IFNs during e.g. viral infections or certain cancers sometimes develop 
symptoms of systemic autoimmune disease, which strongly suggests that IRGs are the driving force 
in these diseases (65, 66). Determining the role of IRGs in the immune system is important for 
understanding the pathology behind IFN-driven systemic autoimmune disease.  
 
In paper I, we link type I IFNs with decreased levels of miR-150-5p and increased levels of its 
target c-Myb. miR-150-5p was specifically downregulated in monocytes after IFNb administration 
in MS patients with a decrease in both cellular and circulating miR-150-5p. Monocytes have been 
reported to secrete miR-150-5p, however we cannot be certain if the observed decrease in 
circulating miR-150-5p is due to decreased release from monocytes or due to reduced levels of 
monocytes in response to the IFNb-treatment (88). We also observed an increase in the miR-150-
5p target c-Myb in SLE patients and an increased level of c-Myb target transcripts. miR-150-5p 
and c-Myb are therefore affected in both acute and chronic IFN responses. c-Myb has previously 
been reported to be overexpressed in SLE and c-Myb expression levels have been correlated to 
disease activity in SLE (102, 103). This could be a reflection of the IFN signature, which correlates 
with disease activity in SLE (60, 61). c-Myb is a proto-oncogene and is a key regulator of 
hematopoiesis (104). The fact that one or several proto-oncogenes are indirectly upregulated by 
type I IFNs is interesting and counterintuitive, since type I IFNs are used as cancer therapy (105). 
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Interestingly, patients with SS have an elevated risk of developing certain neoplasms, most 
commonly non-Hodgkin lymphoma (106). The chronic effects of IFN-signaling and c-Myb 
expression could then in part contribute to this. There is in vitro based evidence that circulating 
miR-150-5p could be taken up by cells and bind to c-Myb (88). Less circulating miR-150-5p could 
then potentially affect c-Myb expression in B cells. c-Myb has also been reported to block 
monocyte differentiation (107, 108). Monocytes from SLE patients have distinct features compared 
with healthy controls, such as increased sensitivity to apoptosis (109). Also, miR-150-5p levels are 
reduced in intermediate monocytes compared with classical and non-classical monocytes (110). 
Our data suggest that the aberrant features of SLE monocytes can in part be explained by the IFN-
mediated decrease of miR-150 and the concomitant increase in c-Myb expression. 
 
In paper III, we identify TRIM21 as an ISG and in paper IV we describe how TRIM21 regulates 
the immune response by negatively affecting the activity of members of the IRF transcription 
family. TRIM21 is also known as Ro52 and is an autoantigen in several systemic autoimmune 
diseases such as SLE and SS. Additionally, TRIM21 is overexpressed in SLE and pSS (111). The 
role of TRIM21 as a negative regulator of the immune system is hard to connect to the 
development of autoimmune disease, however, TRIM21 overexpression could simply be a “side 
effect” of the IFN-signature in these diseases. Autoantibodies directed towards the RING domain 
of TRIM21, isolated from patients with pSS, can indeed block the ubiquitinating activity of 
TRIM21 (112). However, it is not known if the autoantibodies will ever reach TRIM21 since it 
predominantly resides in the cytoplasm (113). As mentioned, we and others have reported that 
TRIM21 regulates members of the IRF transcription family. There are however conflicting reports 
on the outcome of the ubiquitination of IRFs by TRIM21. For an example, Yang et al. report that 
TRIM21 is essential to sustain IRF3 activity (114) while Higgs et al. report TRIM21-mediated 
degradation of IRF3 (52). Therefore, TRIM21 could regulate members of the IRF family differently 
in different situations. Hence, we cannot exclude that the ubiquitination of IRFs by TRIM21 could 
lead to the upregulation of certain genes important for the development of autoimmune disease. 
 
We made an attempt to understand if the overexpression of TRIM21, without the simultaneous 
effect of other ISGs, could contribute to the pathology of autoimmune disease by generating a 
conditional knock-in mouse for TRIM21. We inserted cDNA encoding FLAG-tagged TRIM21 
into the ROSA26 locus, enabling TRIM21 overexpression in all tissues in both embryonic and 
adult mice. To prevent constitutive overexpression of Trim21, a floxed stop cassette was introduced 
upstream of FLAG-TRIM21.  In order for TRIM21 to be expressed the mouse has to be crossed 
	 23	
with another mouse expressing Cre recombinase under the promoter of choice. With this system, 
it is possible to control the expression of Trim21 in a spatial and temporal manner, and to detect 
Trim21-overexpressing cells by green fluorescent protein (GFP) fluorescence. We crossed the mice 
with Vav1-Cre mice so that Trim21 would be overexpressed in all hematopoietic cells, and could 
confirm successful recombination by GFP expression in immune cells. There were no apparent 
differences in the mice that were born compared with littermate controls. We immunophenotyped 
the mice and could not see any differences in immune cell populations. The mice were slightly less 
responsive to in vivo poly(I:C) stimulation (Sjöstrand et al., unpublished data). From these 
experiments, we could conclude that TRIM21 overexpression alone is not important for the 
development of autoimmunity in mice. TRIM21 could however play a role in mice genetically 
prone to develop autoimmune disease. This could be tested by crossing the overexpressing 
ROSA26-TRIM21 mice with disease prone mice or by inducing SLE using the pristane injection 
model. 
 
Future studies on understanding the role of TRIM21 in autoimmune disease should focus on 
clarifying the outcome of IRF ubiquitination by TRIM21, and also look for new targets for 
TRIM21. The latter could be done for an example by using the BioID technique (115). In this 
method, a biotin ligase is fused to your protein of choice, e.g. TRIM21, and expressed in cells where 
it biotinylates endogenous potential interaction partners. The biotinylated proteins can then be 
isolated and identified. 
 
5.3. IRFs and the regulation of ISGs 
 
In study II and III, we find that TRIM21 and BAFF expression is controlled by members of the 
IRF family. IRFs are transcription factors acting downstream of PRRs such as TLRs and cytosolic 
PRRs (e.g. RIG-I and MDA-5). More specifically, we found that both TRIM21 and BAFF 
expression were upregulated by IRF1 and IRF2, and downregulated by IRF4 and IRF8 by binding 
to the two respective ISREs (TRIM21 containing three GAAA repeats, and BAFF containing two). 
We tested the ability of all other IRFs (with the exception of IRF6) one by one to induce expression 
of TRIM21 and BAFF, and for BAFF also a combination of IRF3, -5, -7 and -9 as they are known 
to heterodimerize, and they could not affect BAFF or TRIM21 expression. However, it is still 
possible that these other IRFs could affect TRIM21 or BAFF expression after proper activation 
by post-translational modifications (40, 116) while IRF1 and IRF2 can bind ISRE without post-
translational modification (117-119). Since CHX treatment in EL-4 cells completely abolished 
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Trim21 expression after IFN stimulation, the ISGF3 complex containing IRF9 might not be able 
to induce Trim21 expression, or induces it poorly.   
 
IRF2 is generally known to repress IRF1 transcription activation by binding to the same site and 
blocking transcription (120). However, e.g. Oshima et al. has shown that IRF2 can activate gene 
expression of the same gene (Il7) as IRF1 in human (121). IRF1 and IRF2 are induced by type I 
IFNs. IRF1 is also strongly induced by IFNg while our data show that IRF2 is not induced by 
IFNg. IRF4 and IRF8 are not induced by type I IFNs, IRF8 however can be induced by IFNg. It 
could be that in cells where IRF4 and/or IRF8 are expressed, such as T cells and B cells, it is 
important to keep TRIM21 and BAFF basal expression low, and to control the IFN-induced 
expression. This further supports the hypothesis that TRIM21 is important in T cell biology as 
suggested by Ishii et al (122). Our data also shows that neutrophils are the most potent inducers of 
BAFF after type I IFN stimulation, while the induced and the basal expression in T cells and B 
cells is much lower.  
 
With these two studies, we provide further insight into how IRFs can control ISG expression. Both 
IRF1 and IRF2 are important for the IFN-induced expression of these genes while IRF4 and IRF8 
provide a tight regulation, and are perhaps important for keeping the expression of certain ISGs 
lower in certain cell types. As mentioned, the ISGF3 complex is a weak inducer of Trim21 gene 
expression, however all IRFs have the potential to bind ISRE. There are therefore additional 
regulatory mechanisms controlling the specificities or affinity for IRF binding to ISRE.  
 
Future studies on how different numbers of GAAA repeats in the ISRE are important for the 
control of ISGs by IRFs could provide new insight in ISG regulation. Genes containing triple or 
double GAAA repeats in tandem, are more strongly induced by IFN than genes containing single 
or double GAAA repeats (123). Perhaps the number of GAAA repeats is also important for the 
negative control of certain ISGs by IRF4 and IRF8.  
 
5.4. Is there a link between type I IFNs and the development of eosinophils in the 
bone marrow?  
 
In study IV, we observed that Trim21-/- mice were prone to develop contact hypersensitivity with 
granulocyte infiltrations. In study V, we immunophenotyped naïve Trim21-/- mice and observed a 
double frequency of eosinophils in blood and elevated levels in tissues compared with Trim21+/+ 
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mice. Eosinophils have recently been linked to the Th17 pathway where GM-CSF induced by IL-
23 leads to eosinophil accumulation and subsequent intestine inflammation as well as increased 
production of eosinophils in the bone marrow in a T cell transfer model of IL-23-driven colitis 
(124). We thus propose that TRIM21 can regulate the IL-23/Th17 pathway by ubiquitinating 
members of the IRF family. Interestingly, type I IFN has been shown to inhibit Th17-mediated 
inflammation in EAE, a mouse model for MS (81). In all, this suggests that there is a link between 
type I IFNs, TRIM21, the Th17 pathway and eosinopoiesis.  
 
We did not observe an increase in the canonical cytokines IL-5 nor Eotaxin-1 in the Trim21-/- mice, 
indicating that TRIM21 regulates eosinopoiesis via non-canonical factors, either one or several 
cytokines or a molecule expressed on the cell surface acting via cell-cell contact. Since no other 
granulocyte population was affected, the factor must be specific for eosinophils, which leaves out 
a number of canonical cytokines involved in eosinophil development including GM-CSF. In study 
IV, we observed that TRIM21 is expressed in endothelial cells in naïve GFP expressing Trim21+/- 
mice. Endothelial cells contribute to the bone marrow microenvironment which is important for 
hematopoiesis, and these cells could therefore be potential producers of the TRIM21-regulated 
factor(s).  
 
The increase of infiltrating granulocytes in the Trim21-/- mice suggests that the lack of Trim21 could 
worsen the outcome in a model where one triggers hypereosinophilia e.g. asthma. This is however 
yet to be tested. In future studies, we will focus on finding the TRIM21-regulated factor(s) 
controlling eosinopoiesis in the bone marrow and what cells that are producing it. To find the 
factor(s), we will look in the bone marrow where the eosinopoeisis occurs rather than in sera. For 
an example, we could isolate mature eosinophils in the bone marrow and perform RNA sequencing 
and compare with immature eosinophils to find expression patterns that could result from known 
signaling pathways. To rescue the eosinophilic phenotype, we are crossing the conditional knock-
in ROSA26-TRIM21 mice to Trim21-/- and Vav1-Cre expressing mice. Using the TRIM21 knock-
in mice on a Trim21-/- background and crossing them to different Cre expressing mice could also 
help us to identify what cell that is producing the unknown factor. For an example, we could cross 
the mice with Tie2-Cre (Tek-Cre) where Cre is expressed in endothelial cells. 
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5.5. IRGs and clinical relevance 
 
The more we know about the molecular mechanism behind a disease, the more likely it is to identify 
drug targets. And the more we know about the role of a potential drug target under normal 
conditions, the better we can predict toxic side-effects when targeting it for therapy.  
 
Targeting the IFN pathway has shown promising results in clinical trials for SLE, however in e.g. 
MS, HES and certain cancers type I IFNs are administered as therapy. The fact that type I IFNs 
are the driving force in one autoimmune disease while improves the clinical outcome of another 
highlights the complexity of the IFN signaling response. Since type I IFNs are important for the 
defense of viral infections, blocking their function could lead to severe infections and potential 
reactivation of latent infections. Administering type I IFNs on the other hand, leads to a very 
strong immune response with the upregulation of a great number of genes causing severe side 
effects. It is not clear how type I IFNs are causing disease nor how they are beneficial in treating 
disease. In this thesis, we have identified IRGs and investigated their role in the immune system to 
better understand the IFN-response and its role in disease, and to potentially find new drug targets. 
 
miR-150-5p mimics could potentially be delivered as a therapy in SLE to block B cell development 
and antibody production. However, due to the promiscuous nature of miRNAs, it is hard to predict 
toxic side-effects. miR-150-5p could on the other hand be used as a biomarker, as previously 
proposed by Bergman et al. (125). Follow-up studies on IFN-treatment outcome in MS patients 
could perhaps tell us if miR-150-5p can predict the response to IFNb  in individual patients. 
 
BAFF is targeted for therapy in autoimmune disease due to its role in regulating B cell survival, 
differentiation, maturation, immunoglobulin class switching and antibody production (126). Anti-
BAFF monoclonal antibodies (belimumab) is the first approved biologic for SLE by the U.S. Food 
and Drug Administration, and has shown promising results in phase II clinical trials for pSS (101, 
127). In paper II, we study the molecular mechanism behind the regulation of BAFF and show 
that its expression is controlled by IRFs. The different IRFs have different expression patterns and 
control different sets of IRGs, e.g. our data from paper III shows that TRIM21 expression is 
upregulated by IRF1 and IRF2 and not by other IRFs. This would make IRFs interesting drug 
targets since one could target a specific axis of the IFN response. For an example, IRF7 is mediating 
the TLR-induced massive type I IFN production by pDCs in SLE. By targeting IRF7 instead of 
type I IFNs in general, type I IFNs could still be induced after viral infections. Unfortunately, 
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transcription factors are usually poor drug targets due to their structural properties. However, it 
might be possible to target proteins mediating post-transcriptional modification on IRFs. 
 
As previously mentioned, type I IFNs are successfully used to decrease eosinophil numbers in HES 
patients who respond poorly to corticosteroids. This suggests that one or several ISGs can regulate 
eosinopoiesis. In study V, we identify the ISG TRIM21 as a negative regulator of eosinopoesis via 
one or several unknown factors. Identifying this factor could lead to a new drug target for HES 
that could replace type I IFNs which has many unbeneficial and severe side-effects.   
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